Shanghai Jiao Tong University School of Medicine, Tongren Hospital, Department of Otorhinolaryngology, Shanghai, China.
Zhengzhou Shuqing Medical College, Zhengzhou, China.
Braz J Otorhinolaryngol. 2024 Mar-Apr;90(2):101384. doi: 10.1016/j.bjorl.2023.101384. Epub 2023 Dec 26.
Laryngeal cancer, characterized by high recurrence rates and a lack of effective biomarkers, has been associated with cuproptosis, a regulated cell death process linked to cancer progression. In this study, we aimed to explore the roles of cuproptosis-related genes in laryngeal cancer and their potential as prognostic markers and therapeutic targets.
We collected comprehensive data from The Cancer Genome Atlas and Gene Expression Omnibus databases, including gene expression profiles and clinical data of laryngeal cancer patients. Using clustering and gene analysis, we identified cuproptosis-related genes with prognostic significance. A risk model was constructed based on these genes, categorizing patients into high- and low-risk groups for outcome comparison. Univariate and multivariate analyses were conducted to identify independent prognostic factors, which were then incorporated into a nomogram. Gene Set Enrichment Analysis was employed to explore pathways distinguishing high- and low-risk groups.
Our risk model, based on four genes, including transmembrane 2, dishevelled binding antagonist of β-catenin 1, stathmin 2, and G protein-coupled receptor 173, revealed significant differences in patient outcomes between high- and low-risk groups. Independent prognostic factors were identified and integrated into a nomogram, providing a valuable tool for prognostic prediction. Gene Set Enrichment Analysis uncovered up-regulated pathways specifically associated with high-risk patient samples.
This study highlights the potential of cuproptosis-related genes as valuable prognostic markers and promising therapeutic targets in the context of laryngeal cancer. This research sheds light on new avenues for understanding and managing this challenging disease.
Level 4.
喉癌具有高复发率和缺乏有效生物标志物的特点，与调控细胞死亡过程铜死亡有关，铜死亡与癌症进展有关。在这项研究中，我们旨在探讨铜死亡相关基因在喉癌中的作用及其作为预后标志物和治疗靶点的潜力。
我们从癌症基因组图谱和基因表达综合数据库中收集了全面的数据，包括喉癌患者的基因表达谱和临床数据。使用聚类和基因分析，我们确定了具有预后意义的铜死亡相关基因。基于这些基因构建了风险模型，将患者分为高风险和低风险组进行预后比较。进行单因素和多因素分析以确定独立的预后因素，并将其纳入列线图。采用基因集富集分析探讨区分高风险和低风险组的途径。
我们的风险模型基于四个基因，包括跨膜蛋白 2、β-连环蛋白的卷曲结合拮抗剂 1、微管蛋白 2 和 G 蛋白偶联受体 173，显示高风险和低风险组患者结局存在显著差异。确定了独立的预后因素并将其整合到列线图中，为预后预测提供了有价值的工具。基因集富集分析揭示了与高风险患者样本相关的上调途径。
本研究强调了铜死亡相关基因作为喉癌有价值的预后标志物和有前途的治疗靶点的潜力。这项研究为理解和管理这种具有挑战性的疾病提供了新的途径。
4 级。
